Casey Logan is an advisor for Primmune Therapeutics and Vice President and Head of Corporate Development at Retrophin, a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any treatment options. From February 2013 to March 2018, he served as Chief Business Officer of Tracon Pharamceuticals, a company focused on the development of novel oncology therapeutics. At Tracon, Mr. Logan led all business development and strategy activities, including negotiation and completion of multiple out-licensing and in-licensing transactions and playing a key role in the company's IPO in January 2015. Prior to Tracon, Casey was Senior Vice President, Corporate Development at Bird Rock Bio (formerly RuiYi, Inc.) from January 2011 to February 2013. From 2007 to December 2010, he served as VP, Corporate Development & Strategic Planning at Anadys Pharmaceuticals, Inc. (acquired by Roche). From 2001 to 2007, he was with Eli Lilly and Company in Indianapolis in the corporate business development group, and he was an officer in the U.S. Naval Nuclear Propulsion Program from 1993 to 1999. During his career, Mr. Logan has led transactions in both in-licensing and out-licensing of assets across a range of therapeutic areas, including the creation of two start-up companies. Mr. Logan received an MBA from the Kellogg School of Management at Northwestern University and a B.S.E. in chemical engineering from the University of Michigan.
Stephen Webber, Ph.D.
Co-founder & Advisor
Stephen E. Webber Ph.D. is a Primmune Therapeutics co-founder and advisor and expert in the discovery of TLR7 agonists. He is currently Executive Director of Medicinal Chemistry at Polaris Pharmaceuticals, where he is responsible for the discovery and synthesis of small molecule cancer therapeutics utilizing structure-based drug design techniques. Prior to joining Polaris, Dr. Webber was a co-founder and Director of Medicinal Chemistry at eFFECTOR Therapeutics, a company devoted to the discovery and development of translation regulators for cancer. At eFFECTOR, Dr. Webber’s responsibilities included building and managing a Medicinal Chemistry group, laboratories, and chemistry outsourcing, and performing structure-based drug design. Before this position, Dr. Webber was in charge of leading the discovery chemistry efforts at Anadys Pharmaceuticals, where he served in various senior level positions until the company was acquired by Roche. At Anadys, Dr. Webber discovered and co-invented several therapeutically important antiviral and anticancer small molecules, including clinical candidate setrobuvir, and TLR7 agonists ANA-975 and ANA-773. Dr. Webber also discovered rucaparib, which was licensed to Clovis Oncology by Pfizer and was approved by the FDA to treat ovarian cancer (marketed as Rubraca®). It is currently the subject of several Phase 2 and 3 clinical studies in other cancers in patients with the BRCA, or BRCA-like mutations. Dr. Webber’s industrial career extends back to Agouron Pharmaceuticals Inc., joining the company in 1987 at its inception. Dr. Webber received his B.S. from Philadelphia University (now part of Thomas Jefferson University) and his Ph.D. from the University of Pennsylvania.